4-[(6-氯吡啶-3-基)甲基]-1-羟基-2-萘甲酸 | 1350969-01-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 4-[(6-氯吡啶-3-基)甲基]-1-羟基-2-萘甲酸
• 英文名称: 4-[(6-chloropyridin-3-yl)methyl]-1-hydroxy-2-naphthoic acid
• 英文别名: 4-[(6-Chloropyridin-3-yl)methyl]-1-hydroxy-2-naphthoic acid；4-[(6-chloropyridin-3-yl)methyl]-1-hydroxynaphthalene-2-carboxylic acid
• CAS: 1350969-01-5
• 化学式: C₁₇H₁₂ClNO₃
• 分子量: 313.74
• InChiKey: ICCTWPWDERZOHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  70.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[(6-氯吡啶-3-基)甲基]-1-羟基-2-萘甲酸 在 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[(6-chloropyridin-3-yl)methyl]-N-[(1S,2S)-2-hydroxycyclohexyl]-1-methoxy-2-naphthamide
  参考文献：
  名称：

  Identification of a methoxynaphthalene scaffold as a core replacement in quinolizidinone amide M1 positive allosteric modulators

  摘要：

  A series of methoxynaphthalene amides were prepared and evaluated as alternatives to quinolizidinone amide M-1 positive allosteric modulators. A methoxy group was optimal for M-1 activity and addressed key P-gp issues present in the aforementioned quinolizidinone amide series. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.012
• 作为产物：
  描述：

  1-羟基-2-萘甲酸 在 四(三苯基膦)钯 溴 、 三溴化硼 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 溶剂黄146 、 丙酮 为溶剂， 反应 153.0h， 生成 4-[(6-氯吡啶-3-基)甲基]-1-羟基-2-萘甲酸
  参考文献：
  名称：

  [EN] NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  [FR] COMPOSÉS DE NAPHTHALÈNE CARBOXAMIDE, MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1

  摘要：

  本发明涉及式(I)的萘甲酰胺化合物，它们是M1受体阳性变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。

  公开号：

  WO2011149801A1

文献信息

• NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20130059860A1

  公开（公告）日：2013-03-07

  The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的萘甲酰胺化合物，其为M1受体正向变构调节剂，并且可用于治疗与M1受体有关的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含该化合物的制药组合物以及使用该化合物和组合物治疗M1受体介导的疾病。
• Naphthalene carboxamide M1 receptor positive allosteric modulators
  申请人：Beshore Douglas C.

  公开号：US08883850B2

  公开（公告）日：2014-11-11

  The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的萘甲酰胺化合物，它们是M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，例如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包括该化合物的制药组合物以及使用该化合物和组合物治疗M1受体介导的疾病。
• US8883850B2
  申请人：——

  公开号：US8883850B2

  公开（公告）日：2014-11-11
• [EN] NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] COMPOSÉS DE NAPHTHALÈNE CARBOXAMIDE, MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1
  申请人：MERCK SHARP & DOHME

  公开号：WO2011149801A1

  公开（公告）日：2011-12-01

  The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的萘甲酰胺化合物，它们是M1受体阳性变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• Identification of a methoxynaphthalene scaffold as a core replacement in quinolizidinone amide M1 positive allosteric modulators
  作者：Scott D. Kuduk、Christina N. Di Marco、Jonathan R. Saffold、William J. Ray、Lei Ma、Marion Wittmann、Kenneth A. Koeplinger、Charles D. Thompson、George D. Hartman、Mark T. Bilodeau、Douglas C. Beshore

  DOI：10.1016/j.bmcl.2014.01.012

  日期：2014.3

  A series of methoxynaphthalene amides were prepared and evaluated as alternatives to quinolizidinone amide M-1 positive allosteric modulators. A methoxy group was optimal for M-1 activity and addressed key P-gp issues present in the aforementioned quinolizidinone amide series. (C) 2014 Elsevier Ltd. All rights reserved.